Table 2.
Distribution and hazard ratios of glioblastoma patients according to MDM2 SNP309 andTP53 codon 72 polymorphisms.
| Gender | Treatment | |||||||
|---|---|---|---|---|---|---|---|---|
| Males | Females | Surgery alone | Surgery plus radiotherapy | |||||
| N | Hazard Ratio* (95% CI) | N | Hazard Ratio* (95% CI) | N | Hazard Ratio** (95% CI) | N | Hazard Ratio** (95% CI) | |
| MDM2 SNP309 | ||||||||
| TT | 96 | 1 | 47 | 1 | 32 | 1 | 91 | 1 |
| T/G or G/G | 117 | 1.09 (0.82–1.46) | 100 | 0.73 (0.50–1.06) | 88 | 1.09 (0.71–1.66) | 119 | 1.00 (0.74–1.34) |
| T/G | 90 | 1.05 (0.77–1.44) | 76 | 0.81 (0.55–1.21) | 67 | 1.09 (0.70–1.71) | 94 | 1.06 (0.78–1.45) |
| G/G | 27 | 1.22 (0.79–1.90) | 24 | 0.54 (0.32–0.92) | 21 | 1.08 (0.60–1.91) | 25 | 0.82 (0.51–1.30) |
| TP53 codon 72 | ||||||||
| Arg/Arg | 116 | 1 | 72 | 1 | 69 | 1 | 119 | 1 |
| Arg/Pro or Pro/Pro | 78 | 1.23 (0.92–1.64) | 58 | 1.31 (0.91–1.87) | 49 | 1.23 (0.84–1.80) | 86 | 1.33 (1.01–1.77) |
| Arg/Pro | 64 | 1.31 (0.96–1.79) | 47 | 1.38 (0.94–2.02) | 39 | 1.27 (0.85–1.90) | 71 | 1.48 (1.09–2.00) |
| Pro/Pro | 14 | 0.94 (0.53–1.66) | 11 | 1.04 (0.52–2.08) | 10 | 1.07 (0.52–2.20) | 15 | 0.92 (0.53–1.60) |
*
Adjusted for age and treatment.
**
Adjusted for age and gender.
N = numbers of cases.